BMA annual meeting: Pregabalin must be made a controlled drug, BMA saysBMJ 2017; 357 doi: https://doi.org/10.1136/bmj.j3151 (Published 29 June 2017) Cite this as: BMJ 2017;357:j3151
- Tom Moberly
- UK Editor, BMJ
Pregabalin should be reclassified as a controlled drug to tackle widespread problems of misuse and addiction, the BMA has said.
Delegates at the BMA’s annual representative meeting in Bournemouth on 28 June voted in favour of a motion saying that the BMA should “lobby the appropriate authorities to make pregabalin a controlled drug.”
Pregabalin is currently a prescription only drug and is licensed for the treatment of neuropathic pain and …